Unlabelled: Understanding persistent cellular and humoral immune responses to SARS-CoV-2 will be of major importance to terminate the ongoing pandemic. Here, we assessed long-term immunity in individuals with mild COVID-19 up to 1 year after a localized SARS-CoV-2 outbreak. CoNAN was a longitudinal population-based cohort study performed 1.5 months, 6 months, and 12 months after a SARS-CoV-2 outbreak in a rural German community. We performed a time series of five different IgG immunoassays assessing SARS-CoV-2 antibody responses on serum samples from individuals that had been tested positive after a SARS-CoV-2 outbreak and in control individuals who had a negative PCR result. These analyses were complemented with the determination of spike-antigen specific TH cell responses in the same individuals. All infected participants were presented as asymptomatic or mild cases. Participants initially tested positive for SARS-CoV-2 infection either with PCR, antibody testing, or both had a rapid initial decline in the serum antibody levels in all serological tests but showed a persisting T cell immunity as assessed by the detection of SARS-CoV-2 specificity of T cells for up to 1 year after infection. Our data support the notion of a persistent T-cell immunity in mild and asymptomatic cases of SARS-CoV-2 up to 1 year after infection. We show that antibody titers decline over 1 year, but considering several test results, complete seroreversion is rare.

Trial Registration: German Clinical Trials Register DRKS00022416.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880277PMC
http://dx.doi.org/10.3389/fimmu.2022.1095129DOI Listing

Publication Analysis

Top Keywords

sars-cov-2 outbreak
12
sars-cov-2
9
cell immunity
8
immunity mild
8
months months
8
tested positive
8
positive sars-cov-2
8
year infection
8
persistent humoral
4
humoral cd4
4

Similar Publications

Background: High response rates are needed in population-based studies, as nonresponse reduces effective sample size and bias affects accuracy and decreases the generalizability of the study findings.

Objective: We tested different strategies to improve response rate and reduce nonresponse bias in a national population-based COVID-19 surveillance program in England, United Kingdom.

Methods: Over 19 rounds, a random sample of individuals aged 5 years and older from the general population in England were invited by mail to complete a web-based questionnaire and return a swab for SARS-CoV-2 testing.

View Article and Find Full Text PDF

Prevalence and control of hypertension in COVID-19 positive cases.

J Family Med Prim Care

December 2024

Health Education and Promotion, Faculty of Public Health and Health Informatics, Umm Al-Qura University, Alziziah Makkah, Saudi Arabia.

Background: The coronavirus disease (COVID-19) is an infectious disease caused by the newly discovered SARS-CoV-2 virus. Patients diagnosed with COVID-19 experience several complications including hypertension or elevated blood pressure which is a serious medical condition that significantly increases the risks of heart, brain, and kidney diseases.

Objectives: To assess the prevalence and control of hypertension in COVID-19 patients.

View Article and Find Full Text PDF

The transition to virtual learning formats during the COVID-19 pandemic necessitated substantial curricular adjustments to the University of Hawai'i John A. Burns School of Medicine. This study compares student satisfaction and academic performance between the pre-pandemic (up through March 25, 2020) and pandemic (after March 25, 2020) periods.

View Article and Find Full Text PDF

BackgroundEarly detection and characterisation of SARS-CoV-2 variants have been and continue to be essential for assessing their public health impact. In August 2023, Santé publique France implemented enhanced surveillance for BA.2.

View Article and Find Full Text PDF

BackgroundThe first Corona Monitoring Nationwide (RKI-SOEP) study (October 2020-February 2021) found a low pre-vaccine SARS-CoV-2 antibody seroprevalence (2.1%) in the German adult population (≥ 18 years).AimThe objective of this second RKI-SOEP (RKI-SOEP-2) study in November 2021-March 2022 was to estimate the prevalence of SARS-CoV-2-specific anti-spike and/or anti-nucleocapsid (anti-N) IgG antibodies (combined seroprevalence), past infection based on infection-induced seroprevalence (anti-N), and basic immunisation (at least two antigen contacts through vaccination or infection) in individuals aged ≥ 14 years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!